|Bid||48.88 x 800|
|Ask||49.30 x 800|
|Day's Range||48.89 - 49.33|
|52 Week Range||29.56 - 50.00|
|PE Ratio (TTM)||94.65|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.43|
In an effort to stave off Amazon, CVS will roll-out nationwide delivery of prescription medication. Yahoo Finance's Seana Smith, Ethan Wolff-Mann, David Pogue and Rick Newman discuss.
Repligen (RGEN) delivered earnings and revenue surprises of -11.11% and 3.62%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 6 cents. Earnings, adjusted for one-time gains and costs, were 16 cents per share. The results did not meet Wall ...
Record quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM, Mass., Aug. 02, 2018-- Repligen Corporation, a life ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Repligen Corporation (NASDAQ: RGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:30 AM Eastern Time. ...
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Wall Street snapped its losing streak on Tuesday as investors digested better-than-expected quarterly earnings and after the Trump administration appeared to ...
WALTHAM, Mass., July 19, 2018-- Repligen Corporation today announced that the Company will report its second quarter of 2018 financial results on Thursday, August 2, 2018. The Company will issue a press ...
This means that investors who seek to profit from falling equity prices are currently targeting RGEN. Over the last month, growth of ETFs holding RGEN is favorable, with net inflows of $9.18 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
In multiple successive trials, Praesto® Jetted A50 has consistently shown significantly improved performance over today's market leading Protein A resins, due to the unique benefits of an innovative new ligand coupled to a novel jetted base matrix.
Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact™ A, which will be commercialized by Purolite Life Sciences using their novel Praesto® agarose jetting base bead technology. Repligen is a longtime market leader in Protein A, with two facilities that produce the majority of the global Protein A ligand demand to biopharmaceutical customers worldwide. NGL-Impact™ A was developed as part of Repligen’s collaboration with Navigo Proteins GmbH.
Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH (“Navigo”) for the advancement of exclusive novel affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. Under the terms of this agreement, Repligen and Navigo will co-develop a portfolio of next generation ligands, utilizing Navigo’s proprietary Precision Capturing™ technology platform.
NEW YORK, June 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Matthews ...
WALTHAM, Mass., May 30, 2018-- Repligen Corporation, a global bioprocessing company focused on the development and commercialization of innovative technologies to improve biopharmaceutical manufacturing ...
Repligen Corporation (RGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
WALTHAM, Mass., May 23, 2018-- Repligen Corporation, a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing ...
The Waltham, Massachusetts-based company said it had profit of 8 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, were 17 cents per share. The results exceeded Wall Street ...
So we are now well underway with a fresh week of trading in the biotechnology space and, as we reported yesterday, things have gotten off to a pretty volatile start with a whole host of fresh inputs hitting press at the market open on Monday. Tuesday is no different, with more companies putting out data […] The post Biotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron Pharmaceuticals appeared first on Market Exclusive.